Harmony Biosciences

Biotech & Life Sciences · Upper Merion Township, United States · Founded 2017 · IPO 2020

Harmony Biosciences is a biopharmaceutical company focused on developing and commercializing innovative therapies for patients with rare neurological diseases. The company operates in the healthcare sector, specifically targeting conditions that have limited treatment options. Harmony Biosciences serves patients, healthcare providers, and the broader medical community by bringing breakthrough science within reach. The business model revolves around the research, development, and commercialization of novel medications, generating revenue through the sale of these specialized therapies. The company invests heavily in scientific research to identify new clinical possibilities and advance the treatment landscape for rare neurological disorders. Keywords: biopharmaceutical, rare diseases, neurological, innovative therapies, commercialization, healthcare, research, development, novel medications, breakthrough science.

Valuation $1.56B

Revenue $1.02B

EBITDA $297M

Total funding $100–500M

Power Law Unicorn$1–10B valuation tier Thoroughbred$100M+ revenue

Investors

13 investors on Harmony Biosciences's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series B+ 13 investors entered at this stage

Novo Ventures

Fidelity Investments

Nan Fung Group

Vivo Capital

venBio Partners

Valor Equity Partners

Aisling Capital

CRG LP

HBM Healthcare Investments

OrbiMed

Blackstone

JPMorgan Chase & Co

Victory Capital

Global footprint

Where Harmony Biosciences has talent and traffic

Workforce by country

2 countries with
team presence

🇺🇸 United States99.6%

🇮🇳 India0.4%

2 countries shown

Web traffic by country

7.1K monthly visits
across markets

🇺🇸 United States69%

🇮🇳 India23.9%

🇧🇩 Bangladesh2.8%

🇬🇧 United Kingdom2.8%

🇧🇷 Brazil1.4%

Top 5 markets shown

Talent graph

The shape of Harmony Biosciences's talent

Dealroom maps Harmony Biosciences's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

7 team members profilednamed & role-tagged by Dealroom

350 employeestotal headcount

4 executives & foundersidentified by name

DimensionScore

AI Talent

Engineering

Product

Go-to-market

Leadership

Research

Book a demo to unlock Harmony Biosciences's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Patent intelligence

$55M patent portfolio · 32 active families

Estimated portfolio value

$55M

3.5% of market cap · 8.5× smaller than top peer Jazz Pharmaceuticals ($463M)

32 active patent families

Where Harmony Biosciences innovates CannabidiolDiseaseEndocrinologyInternal medicineMedicinal chemistry

Where Harmony Biosciences concentrates vs peers

Each axis is a top-10 topic across Harmony Biosciences and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Harmony Biosciences

An AI-synthesized read of the highest-engagement posts about Harmony Biosciences on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Harmony Biosciences on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles